To estimate the importance of improved glucose control, insulin sensitivity, weight loss and metformin medication for the proteomic variance during treatment, we determined the first linear discriminant of the comparison between baseline and 3 months of diabetes treatment (LD1treat) and performed a relative importance analysis (Fig. 3d). This evidence concerns the gene INS and diabetes mellitus.